Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Overview | Financials
Company Name Tarsus Pharmaceuticals, Inc.
Symbol TARS
Currency USD
Price 47.3
Market Cap 1,799,372,410
Dividend Yield 0%
52-week-range 14.93 - 48.6
Industry Biotechnology
Sector Healthcare
CEO Dr. Bobak R. Azamian M.D.
Website https://www.tarsusrx.com

An error occurred while fetching data.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to

Related Stocks

AxoGen, Inc. logo

AxoGen, Inc.

AXGN

13.95 USD

ADMA Biologics, Inc. logo

ADMA Biologics, Inc.

ADMA

19.37 USD

Akoya Biosciences, Inc. logo

Akoya Biosciences, Inc.

AKYA

2.73 USD

Protagonist Therapeutics, Inc. logo

Protagonist Therapeutics, Inc.

PTGX

46.76 USD

Sight Sciences, Inc. logo

Sight Sciences, Inc.

SGHT

5.21 USD

OrganiGram Holdings Inc. logo

OrganiGram Holdings Inc.

OGI

1.73 USD

Agenus Inc. logo

Agenus Inc.

AGEN

4.05 USD

Repare Therapeutics Inc. logo

Repare Therapeutics Inc.

RPTX

3.58 USD

Financials

Numbers are in millions USD

Numbers are in millions USD